Clinical Trials Logo

Postreperfusion Syndrome clinical trials

View clinical trials related to Postreperfusion Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05754242 Recruiting - Clinical trials for Liver Transplantation

Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation

VITACTOH
Start date: November 17, 2020
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in preventing the postreperfusion syndrome in liver transplantation. The main questions it aims to answer are: - Can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation ? - Can ascorbic acid decrease the incidence of liver graft dysfunction after liver transplantation? - Can ascorbic acid decreased the incidence of postoperative complications after liver transplantation ? Participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or 100 ml of saline alone, during the anhepatic phase of liver transplantation before reperfusion of the new graft. Researchers will compared the incidence of postreperfusion syndrome in both groups.

NCT ID: NCT01886664 Completed - Clinical trials for Liver Transplantation

Comparison of PRS According to Inhalation Agent During LDLT

Start date: December 2012
Phase: Phase 4
Study type: Interventional

The investigators tried to evaluate the effect of desflurane on the incidence of postreperfusion syndrome during living donor liver transplantation surgery. The investigators used sevoflurane as a comparison.

NCT ID: NCT01001403 Completed - Clinical trials for Liver Transplantation

Effect of Nafamostat on Postreperfusion Syndrome (PRS)

Start date: March 2009
Phase: Phase 4
Study type: Interventional

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.